Dr. Daniel Von Hoff, TGen ‘s World Renowned Physician-in-Chief Honored By Columbia University For Excellence in Clinical Medicine
May 8, 2017
Edited For Style and Space
Dr. Daniel Von Hoff – Distinguished Professor, Physician-In-Chief, and Director of Molecular Medicine at the Translational Genomics Research Institute (TGen) – will receive a Gold Medal for Excellence in Clinical Medicine from his alma mater, Columbia University.
Columbia University College of Physicians and Surgeons Alumni Association will present the award May 13, 2017 in New York City to Dr. Von Hoff, a world-renowned expert in new therapies for patients with cancer and pancreatic cancer clinical research.
“This medal represents the highest honor which the Alumni Association can bestow in recognition of your outstanding accomplishments,” said Dr. Kenneth A. Forde, chair of the Physicians and Surgeons Alumni Association Honors and Awards Committee, which represents some of the nation’s most accomplished medical professionals.
This year marks the 250th anniversary of P&S, and its founding as the first medical school in Colonial America to award an Medical Doctorate degree.
Dr. Daniel Von Hoff is also a Senior Consultant-Clinical Investigations for City of Hope, Chief Scientific Officer at HonorHealth Research Institute, and Professor of Medicine at Mayo Clinic. He currently co-leads an international Stand Up To Cancer (SU2C) Pancreatic Cancer Dream Team, developing new treatments for this disease. It is one of three SU2C Dream Team grants awarded to TGen.
He graduated cum laude from Carroll University (1969), and received his M.D. from Columbia University College of Physicians and Surgeons (1973). He completed his internship and residency in internal medicine at the University of California, San Francisco, then completed a medical oncology fellowship at the National Cancer Institute.
Dr. Von Hoff is a past director of the University of Arizona’s Arizona Cancer Center. He also is a past board member and president of the American Association for Cancer Research (AACR), a Fellow of the AACR, and recipient of the distinguished AACR Richard and Hinda Rosenthal Memorial Award. In addition, he is a past board member of the American Association of Clinical Oncology (ASCO) and winner of its prestigious David A. Karnofsky Memorial Award for outstanding contributions to patient care and treatment.
He served a six-year term on President Bush’s National Cancer Advisory Board (2004-10); is a recipient of the Wallace A. Reed M.D. Award, recognizing his accomplishments in advancing innovative cancer treatments, from the Arizona Medical Association; and received the Award of Excellence from the Hope Funds for Cancer Research, for his work in the clinical development of many new cancer treatments.
Dr. Von Hoff and his colleagues have conducted early clinical investigations of many new cancer agents, including: Gemcitabine, Docetaxel, Paclitaxel, Topotecan, Irinotecan, Nanoliposomal Irinotecan, Fludarabine, Mitoxantrone, Dexrazoxane, Nab-paclitaxel, Vismodegib, and others. These treatments are helping many patients with pancreatic cancer as well as breast, ovarian, prostate, colon, leukemia, and advanced basal cell cancers.
More About Dr. Daniel Von Hoff
Dr. Von Hoff, Trailblazer
Dr. Von Hoff Named Giant of Cancer Care
Inducted Into Joshua Lederberg Society
Scripps Genomic Medicine Award
American Society of Clinical Oncology Award
Abraxane Acts Like A Trojan Horse
Pursuing The Scar: Latest State of Pancreas Cancer
Top Honor From Arizona Medical Association
Return To Pancreatic Cancer News